- Home
- REI vs NGNE Comparison
REI vs NGNE Comparison
Compare REI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- NGNE
- Stock Information
- Founded
- REI 2004
- NGNE 2003
- Country
- REI United States
- NGNE United States
- Employees
- REI N/A
- NGNE N/A
- Industry
- REI Oil & Gas Production
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- NGNE Health Care
- Exchange
- REI Nasdaq
- NGNE Nasdaq
- Market Cap
- REI 241.9M
- NGNE 251.9M
- IPO Year
- REI N/A
- NGNE N/A
- Fundamental
- Price
- REI $0.81
- NGNE $17.86
- Analyst Decision
- REI
- NGNE Strong Buy
- Analyst Count
- REI 0
- NGNE 7
- Target Price
- REI N/A
- NGNE $41.86
- AVG Volume (30 Days)
- REI 4.3M
- NGNE 183.6K
- Earning Date
- REI 08-05-2025
- NGNE 08-08-2025
- Dividend Yield
- REI N/A
- NGNE N/A
- EPS Growth
- REI N/A
- NGNE N/A
- EPS
- REI 0.36
- NGNE N/A
- Revenue
- REI $335,642,768.00
- NGNE $925,000.00
- Revenue This Year
- REI $2.59
- NGNE N/A
- Revenue Next Year
- REI $17.45
- NGNE N/A
- P/E Ratio
- REI $2.27
- NGNE N/A
- Revenue Growth
- REI N/A
- NGNE N/A
- 52 Week Low
- REI $0.72
- NGNE $6.88
- 52 Week High
- REI $2.06
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- REI 47.63
- NGNE 48.91
- Support Level
- REI $0.81
- NGNE $18.22
- Resistance Level
- REI $0.94
- NGNE $21.43
- Average True Range (ATR)
- REI 0.06
- NGNE 2.15
- MACD
- REI 0.01
- NGNE -0.45
- Stochastic Oscillator
- REI 28.11
- NGNE 19.98
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.